Progyny raised the midpoint of its full-year 2026 guidance after record third-quarter revenue and profit. The fertility benefits company also secured a record 1.3 million new covered lives in its latest selling season. Third-quarter revenue rose nearly 9% from a year earlier. For 2026, Progyny now expects revenue of $1.365 billion to $1.385 billion, adjusted EBITDA of $235 million to $240 million, and net income of $107 million to $110.6 million. Chief executive officer Pete Anevski said the company added more than 85 new clients and retained nearly all existing ones. Most new members launch in the first quarter of 2027. Progyny ended September with $196 million in cash and no debt. It bought back nearly 3 million shares for about $83 million in the quarter.

Progyny (PGNY) ranks no. 7 among analyst picks with strong stock buybacks. By Joel Kornblau, Editor, The Online Investor, Friday, October 30, 2026, 2:22 PM ET Progyny Inc. (PGNY) ranks seventh in a The Online Investor screen combining strong stock buyback activity with favorable brokerage analyst recommendations. To qualify, a company must have repurchased shares equal to at least 5% of its outstanding shares over the trailing 12 months. Qualifying stocks are then ranked by their average analyst recommendation. What the buyback screen shows. The screen identifies companies with substantial recent repurchases that also receive relatively favorable analyst ratings. Those two signals measure different things: repurchases reflect a capital allocation decision, while analyst recommendations reflect external assessments of a company's prospects and valuation. Their alignment can warrant closer examination, but it does not establish that a stock is undervalued. Buybacks can reduce the number of shares outstanding, allowing a given amount of earnings to be spread across fewer shares and potentially raising earnings per share. The effect depends on the net change in share count: shares issued through employee compensation or other transactions can offset repurchases. The price paid for shares and the use of cash that might otherwise fund operations, investment or debt reduction also matter. For Progyny, the key questions are whether repurchases produce a sustained decline in diluted shares outstanding and whether the company can maintain its operating performance while funding them. A trailing 12-month repurchase threshold establishes the scale of recent activity, not its future pace or economic return. Putting Progyny's ranking in context. Progyny provides fertility and family-building benefits services. Its business differs materially from those of hospital operator HCA Healthcare Inc. (HCA) and managed-care company Centene Corp. (CNC). The three-month price chart below compares their stock performance, but differences in their business models limit what a direct valuation comparison would show. Progyny's seventh-place ranking highlights the combination of its recent repurchase activity and analyst support. Assessing the significance of that combination requires looking beyond the rank to net share-count changes, the company's operating results and the value obtained for each dollar spent on repurchases. How to read broker darling screens and IPO and secondary context. Broker darling stories highlight stocks that analysts currently favor within a large-cap or dividend-oriented screen. IPO and secondary offering stories can affect supply, dilution, liquidity, and investor expectations. The signal is most useful when analyst support is reviewed with valuation, earnings expectations, dividend quality, and business fundamentals. Investors should treat the ipo and secondary context angle as context rather than a standalone signal.

StockStory has picked one cash-producing stock to buy and two to sell, arguing that strong cash flow means little if a company fails to put it to work. The buy is APA Corporation, an oil and gas producer with a trailing 12-month free cash flow margin of 23.7%. Revenue is $8.37 billion, and it has grown 4.9% a year over the last decade. Gross margin is 67.7%. The shares trade at $50.51, or 8.3x forward P/E. The sells are Progyny and Goodyear. Progyny has a 13.6% free cash flow margin and $1.31 billion in revenue, but weak unit sales and flat adjusted operating margin. Its shares trade at $27.77, or 12.9x forward P/E. Goodyear's margin is 1.1%. Sales have fallen 4.5% a year over two years, and new share issuance cut earnings per share by 17.7% a year over five. Its shares trade at $4.41.